Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.